L-S,R-buthionine sulfoximine:: historical development and clinical issues

被引：161

作者：

Bailey, HH ^{[1
]}

机构：

[1] Univ Wisconsin, Dept Med, Ctr Comprehens Canc, Madison, WI 53792 USA

来源：

CHEMICO-BIOLOGICAL INTERACTIONS | 1998年 / 112卷

关键词：

L-S; R-buthionine sulfoximine; glutathione; tumor;

D O I：

10.1016/S0009-2797(97)00164-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

L-S,R-buthionine sulfoximine (L-S,R BSO) is a potent specific inhibitor of gamma-glutamylcysteine synthetase, the rate-limiting step in glutathione (GSH) biosynthesis. GSH is an important component of tumor drug resistance based on a strong association and recent transfection studies. Depletion of intracellular GSH by BSO significantly enhances the cytotoxicity of many cytotoxic agents, principally alkylating agents and platinating compounds but also irradiation and anthracyclines. Phase I clinical trials of BSO + melphalan (L-PAM)have been carried out and observed little toxicity with BSO alone and increased myelosuppression with BSO + L-PAM. Consistent and profound ( < 10% of control) GSH depletion was observed in serial determinations of tumor GSH levels in patients receiving continuous infusion (CI) BSO. Evidence of clinical activity has been observed in patients with alkylating or platinating agent-refractory tumors. Phase II evaluation of CI BSO with L-PAM is in progress. (C) 1998 Published by Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：239 / 254

页数：16

共 39 条

[1] NITROGEN MUSTARD-DNA INTERACTION IN MELPHALAN-RESISTANT MAMMARY-CARCINOMA CELLS WITH ELEVATED INTRACELLULAR GLUTATHIONE AND GLUTATHIONE-S-TRANSFERASE ACTIVITY [J].

ALAOUIJAMALI, MA ;

PANASCI, L ;

CENTURIONI, GM ;

SCHECTER, R ;

LEHNERT, S ;

BATIST, G .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 30 (05) :341-347

[2]

ALIOSMAN F, 1989, CANCER RES, V49, P5258

[3]

ALLALUNISTURNER MJ, 1988, CANCER RES, V48, P3657

[4] Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines [J].

Anderson, CP ;

Tsai, J ;

Chan, W ;

Park, CK ;

Tian, L ;

Lui, RM ;

Forman, HJ ;

Reynolds, CP .

EUROPEAN JOURNAL OF CANCER, 1997, 33 (12) :2016-2019

[5]

ANDREWS PA, 1985, CANCER RES, V45, P6250

[6]

ARRICK BA, 1984, CANCER RES, V44, P4224

[7] PHASE-I CLINICAL-TRIAL OF INTRAVENOUS L-BUTHIONINE SULFOXIMINE AND MELPHALAN - AN ATTEMPT AT MODULATION OF GLUTATHIONE [J].

BAILEY, HH ;

MULCAHY, RT ;

TUTSCH, KD ;

ARZOOMANIAN, RZ ;

ALBERTI, D ;

TOMBES, MB ;

WILDING, G ;

POMPLUN, M ;

SPRIGGS, DR .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) :194-205

[8] Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan [J].

Bailey, HH ;

Ripple, G ;

Tutsch, KD ;

Arzoomanian, RZ ;

Alberti, D ;

Feierabend, C ;

Mahvi, D ;

Schink, J ;

Pomplun, M ;

Mulcahy, RT ;

Wilding, G .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (23) :1789-1796

[9]

BAILEY HH, 1992, CANCER RES, V52, P5115

[10] COMPARISON OF NITROGEN-MUSTARD-SENSITIVE AND -RESISTANT YOSHIDA SARCOMAS [J].

BALL, CR ;

CONNORS, TA ;

DOUBLE, JA ;

UJHAZY, V ;

WHISSON, ME .

INTERNATIONAL JOURNAL OF CANCER, 1966, 1 (04) :319-+

← 1 2 3 4 →